drugset
drugset / Trial / NCT02372240

A Study of VLX1570 and Dexamethasone in Myeloma Patients

NCT02372240 ↗

Phase 1/2 Terminated 15 enrolled Vivolux AB Theradex · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase 1/2 single arm study to determine the safety and efficacy of VLX1570 IV infusion administered with low dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.

Timeline

Start
2015-04-08
Primary completion
2017-05-24
Completion
2017-05-24

Outcome

Outcome not reported

Stopped: “Dose limiting tox is observed. Study put on full clinical hold.”

Drugs

EvaluationDrugModalityDoseRoute
Subject VLX1570 Unknown 0.05 mg/kg Intravenous
Subject VLX1570 Unknown 0.15 mg/kg Intravenous
Subject VLX1570 Unknown 0.3 mg/kg Intravenous
Subject VLX1570 Unknown 0.6 mg/kg Intravenous
Subject VLX1570 Unknown 1.2 mg/kg Intravenous
Subject VLX1570 Unknown 2 mg/kg Intravenous
Background Dexamethasone Small molecule 20 mg Oral

Indications

plasma cell myeloma